High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$856K
$856,000
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| AVTX |
Avalo Therapeutics, Inc.
|
CFO
10b5-1 Sell
|
2026-04-02 | $136,823x2 | S | Form 4 |
|
AVTX
S
Avalo Therapeutics, Inc.
Doyle Mittie
• Officer • Chief Medical Officer
10b5-1 SellΔOwn -15.8%
2026-04-01
$10,864
|
||||||
| AVTX |
Avalo Therapeutics, Inc.
|
Officer • Chief Medical Officer
10b5-1 SellΔOwn -15.8%
|
2026-04-01 | $10,864 | S | Form 4 |
| AVTX |
Avalo Therapeutics, Inc.
|
CFO
10b5-1 Sell
|
2026-04-01 | $133,770x2 | S | Form 4 |
|
AVTX
S
Avalo Therapeutics, Inc.
Doyle Mittie
• Officer • Chief Medical Officer
10b5-1 SellΔOwn -87.6%
2026-03-16
$411,607
|
||||||
| AVTX |
Avalo Therapeutics, Inc.
|
Officer • Chief Medical Officer
10b5-1 SellΔOwn -87.6%
|
2026-03-16 | $411,607 | S | Form 4 |
|
AVTX
S
Avalo Therapeutics, Inc.
Goldman Jonathan
• Director
Discretionary Sell
2025-11-14
$162,937x2
|
||||||
| AVTX |
Avalo Therapeutics, Inc.
|
Director
Discretionary Sell
|
2025-11-14 | $162,937x2 | S | Form 4 |